REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Aug 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-08-25

Reporting Person: Sanofi (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-25	Common Stock	P	3684	$479.1912	Acquired	23811843	Indirect
2017-08-25	Common Stock	P	28586	$479.9313	Acquired	23840429	Indirect
2017-08-25	Common Stock	P	21360	$480.7489	Acquired	23861789	Indirect
2017-08-25	Common Stock	P	1302	$481.6284	Acquired	23863091	Indirect
2017-08-25	Common Stock	P	4485	$482.8734	Acquired	23867576	Indirect
2017-08-25	Common Stock	P	2000	$484.21	Acquired	23869576	Indirect
2017-08-25	Common Stock	P	5723	$485.2798	Acquired	23875299	Indirect
2017-08-25	Common Stock	P	2681	$485.9939	Acquired	23877980	Indirect
2017-08-25	Common Stock	P	2557	$487.0108	Acquired	23880537	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $478.42 to $479.39 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $479.43 to $480.39 per share, inclusive.

F6: Purchase prices range from $480.44 to $481.32 per share, inclusive.

F7: Purchase prices range from $481.47 to $482.09 per share, inclusive.

F8: Purchase prices range from $482.49 to $483.45 per share, inclusive.

F9: Purchase prices range from $483.70 to $484.63 per share, inclusive.

F10: Purchase prices range from $484.86 to $485.85 per share, inclusive.

F11: Purchase prices range from $485.86 to $486.79 per share, inclusive.

F12: Purchase prices range from $486.92 to $487.57 per share, inclusive.